

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BAKER BROS. ADVISORS LP (Last) (First) (Middle) 860 WASHINGTON STREET 3RD FLOOR (Street) NEW YORK NY 10014 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol SEATTLE GENETICS INC WA [SGEN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/30/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								107,511 ⁽¹⁾	D	
Common Stock								107,504 ⁽²⁾	D	
Common Stock	04/30/2018		P		154,218	A	\$50.9013 ⁽¹¹⁾	44,509,553	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	04/30/2018		P		248,121	A	\$51.0278 ⁽¹³⁾	44,757,674	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	04/30/2018		P		52,700	A	\$51.0659 ⁽¹⁴⁾	44,810,374	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	04/30/2018		P		168,097	A	\$51.2489 ⁽¹⁵⁾	44,978,471	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		M		10,000	A	\$10.08	5,288,174	I	See footnotes ⁽³⁾⁽⁴⁾⁽⁶⁾⁽⁷⁾⁽⁸⁾⁽¹⁰⁾
Common Stock	05/01/2018		M		10,000	A	\$10.08	44,988,471	I	See footnotes ⁽⁴⁾⁽⁵⁾⁽⁶⁾⁽⁷⁾⁽⁸⁾⁽¹⁰⁾
Common Stock	05/01/2018		P		100,000	A	\$51.14	45,088,471	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		72,533	A	\$51.2552 ⁽¹⁶⁾	45,161,004	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		22,700	A	\$51.2962 ⁽¹⁷⁾	45,183,704	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		10,500	A	\$51.36	45,194,204	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		57,270	A	\$51.3656 ⁽¹⁸⁾	45,251,474	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		37,963	A	\$52.0563 ⁽¹⁹⁾	45,289,437	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/01/2018		P		5,951	A	\$52.3303 ⁽²⁰⁾	45,295,388	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/02/2018		P		2,000	A	\$51.875	45,297,388	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/02/2018		P		37,400	A	\$52.3268 ⁽²¹⁾	45,334,788	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/02/2018		P		21,442	A	\$52.2608 ⁽²²⁾	45,356,230	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾
Common Stock	05/02/2018		P		9,105	A	\$54.4193 ⁽²³⁾	45,365,335	I	See footnotes ⁽⁶⁾⁽⁷⁾⁽¹²⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Options (right to buy)	\$10.08	04/30/2018		M			10,000	05/15/2009	05/16/2018	Common Stock	10,000	(9)	0	I	See Footnotes ⁽³⁾⁽¹⁰⁾
Non-Qualified Stock Options (right to buy)	\$10.08	04/30/2018		M			10,000	05/15/2009	05/16/2018	Common Stock	10,000	(9)	0	I	See Footnotes ⁽⁵⁾⁽¹⁰⁾

1. Name and Address of Reporting Person*

[BAKER BROS. ADVISORS LP](#)

(Last) (First) (Middle)

860 WASHINGTON STREET
3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[667, L.P.](#)

(Last) (First) (Middle)

860 WASHINGTON STREET, 3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Baker Bros. Advisors \(GP\) LLC](#)

(Last) (First) (Middle)

860 WASHINGTON STREET
3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Baker Brothers Life Sciences LP](#)

(Last) (First) (Middle)

860 WASHINGTON STREET
3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[BAKER FELIX](#)

(Last) (First) (Middle)

860 WASHINGTON STREET
3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[BAKER JULIAN](#)

(Last) (First) (Middle)

860 WASHINGTON STREET, 3RD FLOOR

(Street)

NEW YORK NY 10014

(City) (State) (Zip)

Explanation of Responses:

1. Reflects shares of common stock of Seattle Genetics, Inc. (the "Issuer") held directly by Felix J. Baker.
2. Reflects shares of common stock of the Issuer held directly by Julian C. Baker.
3. As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 10,000 shares of Common Stock of the Issuer received upon the exercise of stock options of the Issuer held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. The policy of the Funds (defined below) and Baker Bros. Advisors LP (the "Adviser"), does not permit full-time employees or principals of the Adviser to receive compensation for serving as a Director of the Issuer.
4. The shares of common stock were received upon exercise of 10,000 stock options that were issued to Felix J. Baker in his capacity as a director of the Issuer. Felix J. Baker, pursuant to the policies of the Adviser, does not have any right to the pecuniary interest in the stock options issued for his service on the Board of Directors of the Issuer (the "Board") or the shares of common stock received upon exercise of such stock options. Each of the Funds owns an indirect proportionate pecuniary interest in the shares of common stock received upon exercise of the stock options issued in connection with Felix J. Baker's service on the Board less the exercise cost of those options. Solely as a result of their ownership interest in the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares issued upon exercise of the stock options (i.e. no direct pecuniary interest).
5. As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 10,000 shares of Common Stock of the Issuer received upon the exercise of stock options of the Issuer held by Baker Brothers Life Sciences, L.P. ("Life Sciences"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. The policy of the Funds (defined below) and the Adviser, does not permit full-time employees or principals of the Adviser to receive compensation for serving as a Director of the Issuer.
6. Includes beneficial ownership of 18,100 previously issued restricted stock units payable solely in common shares issued to Felix Baker in his capacity as a director of the Issuer pursuant to the Amended and Restated 2007 Equity Incentive Plan of which the fund may be deemed to own a portion and 50,000 shares, 40,000 of which were received previously, from exercise of 50,000 stock options of the Issuer that were issued to Felix J. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.
7. The Adviser serves as the Investment Adviser to Life Sciences and 667 (collectively the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.
8. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
9. These non-qualified stock options are not priced.
10. The disclosure of the exercise of directors options for shares of common stock reported on this form is a single exercise of 10,000 shares. The 10,000 shares are reported for each of the Funds as each has an indirect pecuniary interest.
11. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.71 to \$51.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
12. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
13. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.91 to \$51.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

14. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$50.67 to \$51.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
15. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.01 to \$52.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
16. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.07 to \$51.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
17. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.10 to \$51.72, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
18. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.27 to \$51.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
19. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.54 to \$52.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
20. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$52.00 to \$52.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
21. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.91 to \$52.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
22. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$51.88 to \$52.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
23. The price reported in Column 4 is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$54.40 to \$54.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Remarks:

Felix J. Baker is a director of Seattle Genetics, Inc. (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

By: Baker Bros. Advisors LP,
Name: Scott L. Lessing, Title: 05/02/2018
President /s/ Scott L. Lessing

Baker Bros. Advisors LP,
Mgmt. Co. and Inv. Adviser to
667. L.P., pursuant to
authority granted by Baker
Biotech Capital L.P., GP to
667. L.P. Name: Scott L.
Lessing, Title: President /s/
Scott L. Lessing 05/02/2018

By: Baker Bros. Advisors (GP)
LLC Name: Scott L. Lessing,
Title: President /s/ Scott L.
Lessing 05/02/2018

Baker Bros. Advisors LP,
Mgmt. Co. and Inv. Adviser to
BAKER BROTHERS LIFE
SCIENCES, L.P., pursuant to
authority granted by Baker
Brothers Life Sciences
Capital L.P., GP to Baker
Brothers Life Sciences, L.P.,
Name: Scott L. Lessing, Title:
President /s/
/s/ Felix J. Baker 05/02/2018
/s/ Julian C. Baker 05/02/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.